Thomas Schön

Thomas Schön is a Professor in the Department of Biomedical and Clinical Sciences (BKV) at Linköping University, affiliated with the Faculty of Medicine and Health Sciences and the Division of Inflammation and Infection (II). His work spans Immunology, Microbiology, and clinical infectious disease management.

His research centers on tuberculosis individualization, targeting the 10 million annual cases through immune system modulation, resistance mechanism analysis, and antibiotic dosing optimization. Projects in Sweden and Ethiopia focus on diagnostics enhancement and treatment personalization for TB and other infectious diseases, emphasizing immune resilience and therapeutic streamlining. Recent work explores host-response biomarkers and drug-resistance dynamics in low-endemic settings.

Publications reveal strong trends in diagnostic innovation for challenging TB forms (extrapulmonary/paucibacillary) and precision pharmacology for drug-resistant strains. Key themes include point-of-care testing validation, weight-based dosing safety, and bedaquiline resistance classification systems requiring standardized reference methods.

Schön coordinates major funded initiatives, notably a SEK 15 million Swedish Research Council grant (June 2021) evaluating Covid-19 vaccination efficacy. His multidisciplinary tuberculosis research group integrates clinical specialists across medical and scientific domains to optimize patient management strategies.